Search
Filters
Clear All
  • 10

Phase

  • 1
  • 1
  • 4
  • 3
  • 10

Found 10 greg-durm-md trials

A listing of greg-durm-md medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma (ELEVATE HNSCC)

G
Greg Durm, MD
18-100 years
All genders
Phase 2
Interventional
What is this study about?The goals of this clinical study are to learn about the safety, tolerability, dosing andveness of the study drug, magrolimab in combination with other anticancer therapies inwith head and neck squamous cell carcinoma (HNSCC). THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology …
Learn More

A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm

G
Greg Durm, MD
18-100 years
All genders
Phase 2
Interventional
This is a research study to find out if giving a drug called pembrolizumab after lung cancer surgery does a better job at keeping the cancer from coming back than surgery alone.
Learn More

A first-in-human, Phase I Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors

G
Greg Durm, MD
18-100 years
All genders
Phase 1
To assess the safety and tolerability of TTX-080
Learn More

A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

G
Greg Durm, MD
18-100 years
All genders
Phase 1/2
To determine the recommended Phase 2 dose (RP2D) of LY3537982 monotherapy in patients with KRAS G12C-mutant advanced solid tumors
Learn More

Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

G
Greg Durm, MD
18-100 years
All genders
Phase 2
Interventional
This phase II trial studies the effects of temozolomide and atezolizumab as second or thirdwith small cell lung cancer that has spread to other places inhe body (metastatic) or has come back (recurrent). Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either …
Learn More

A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients With Advanced Solid Tumors

G
Greg Durm, MD
18-100 years
All genders
This is a Phase 1, open label, multi-center study of orally administered DSP-0337 in adult subjects with advance solid tumors that are refractory to standard treatment, or for whom no effective therapy exists.
Learn More

eFT508 in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone

G
Greg Durm, MD
18-100 years
All genders
This study will evaluate the safety, tolerability, antitumor activity, and pharmacokinetics (PK) of eFT508 in patients who have initiated anti-PD-1/anti-PD-L1 monotherapy and either developed progressive disease (PD) on therapy or have undergone 12 weeks of anti-PD-1/anti-PD-L1 therapy with no evidence of partial response (PR) or complete response (CR).
Learn More

Testing the Addition of Chemotherapy Drug, Cisplatin, to Usual Radiation Therapy for Patients with Head and Neck Cancer

G
Greg Durm, MD
18-100 years
All genders
Phase 2
Interventional
The purpose of this study is to compare two treatment approaches that are currently used after surgery for head and neck cancer. One approach is to administer radiation therapy alone. A second approach is to administer radiation therapy along with the chemotherapy drug, cisplatin.
Learn More

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

G
Greg Durm, MD
18-100 years
All genders
The purpose of this study is to compare any good and bad effects of usual radiation plus the study treatment, MEDI4736 (durvalumab), to the usual therapy of radiation plus cetuximab in patients with head and neck cancer who cannot take the drug cisplatin.
Learn More

A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor

G
Greg Durm, MD
18-100 years
All genders
This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit with a PD-1 or PD-L1 inhibitor.
Learn More